ARDM - Aradigm Corporation
| Previous Close | 0.4600 |
| Open | 0.0000 |
| Bid | 0.00 x 3000 |
| Ask | 0.00 x 900 |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | 0 |
| Avg. Volume | 166,763 |
| Market Cap | 1.832M |
| Beta (3Y Monthly) | 3.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.09 |
| Earnings Date | Mar 27, 2019 - Apr 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1996-03-01 |
| 1y Target Est | 10.00 |
- Business Wire•5 days ago
Aradigm Announces Plans for Reorganization Under Chapter 11 of the U.S. Bankruptcy Code
Aradigm Corporation (ARDM) (“Aradigm” or the “Company”) has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the Alameda County Court District to facilitate the sale of its assets. On February 11, 2019, Aradigm determined that without confirmation of funding from their primary investor and partner, the Company would not have enough funds to meet all of their future financial obligations. As a result, Aradigm’s Board of Directors issued a unanimous consent authorizing Aradigm Corporation to file for protection under Chapter 11 of the U.S. Bankruptcy Code.
- Business Wire•21 days ago
Aradigm Announces Submission of Responses to EMA Day 120 Questions and Meeting with FDA
As part of the EMA regulatory review calendar for marketing authorization application submissions to the EMA for approval, Aradigm will expect a Day 180 List of Outstanding Issues in late March. The clock will stop again until Aradigm responds to those issues, usually within thirty to sixty days. One month later, Aradigm could expect an opinion by the Committee for Medicinal Products for Human Use (CHMP) to our request for approval or a presentation to the CHMP during a formal hearing, which will be followed by the CHMP opinion a month later.
- Business Wire•last month
Aradigm Announces Detailed Third Party Evaluation Results for Apulmiq (FDA)/Linhaliq (EMA)
Aradigm Corporation (ARDM) ("Aradigm" or the "Company") today announced specific, detailed results of an independent third party evaluation (TPE) of the Phase 3 clinical trial results for Apulmiq. As previously reported, Aradigm received a Complete Response Letter (CRL) on 26 January 2018, from the US Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Apulmiq as a treatment for non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infection with Pseudomonas aeruginosa (P. aeruginosa). The CRL identified issues related to a manual re-review of patient-level pulmonary exacerbation (PE) data conducted by Aradigm after errors were discovered in the analyses performed by a contract research organization.
- Business Wire•2 months ago
Aradigm Announces Results of Third Party Verification for Apulmiq (formerly Linhaliq)
Aradigm received a Complete Response Letter (CRL) on 26 January 2018, from the US Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Apulmiq as a treatment for non-cystic fibrosis bronchiectasis patients with chronic lung infection with Pseudomonas aeruginosa (P. aeruginosa). The CRL identified issues related to a manual re-review of patient-level pulmonary exacerbation (PE) data conducted by Aradigm after errors were discovered in the analyses performed by a contract research organization.
- Associated Press•3 months ago
Aradigm: 3Q Earnings Snapshot
On a per-share basis, the Hayward, California-based company said it had a loss of 24 cents. The specialty pharmaceutical company posted revenue of $282,000 in the period. The company's shares closed at ...
- Business Wire•3 months ago
Aradigm Announces Third Quarter 2018 Financial Results
Aradigm Corporation today announced financial results for the third quarter and nine months ended September 30, 2018.
- Associated Press•6 months ago
Aradigm: 2Q Earnings Snapshot
The Hayward, California-based company said it had a loss of 25 cents per share. The specialty pharmaceutical company posted revenue of $256,000 in the period. The company's shares closed at $1.38. A year ...
- Business Wire•6 months ago
Aradigm Announces Second Quarter 2018 Financial Results
Aradigm Corporation today announced financial results for the second quarter and six months ended June 30, 2018.
- Business Wire•8 months ago
Aradigm Announces the Appointment of Dr. Theresa Matkovits to the Board of Directors
Aradigm Corporation (ARDM) (the "Company") today announced the appointment of Dr. Theresa Matkovits to the Board, the Audit Committee of the Board and the Nominating and Corporate Governance Committee of the Board. Dr. Matkovits is Chief Operating Officer of ContraVir Pharmaceuticals (“ContraVir”). Dr. Matkovits has served as ContraVir’s Chief Operating Officer since December 2017, previous to which, she served as Executive Vice President, Head of Drug Development at ContraVir from May 2015 to November 2017.
- Business Wire•9 months ago
Aradigm Announces First Quarter 2018 Financial Results
Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2018.
- ACCESSWIRE•10 months ago
Wired News – EMA Completed Validation of MAA for Aradigm’s Linhaliq in Non-Cystic Fibrosis Bronchiectasis
Stock Monitor: Bio-Path Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Aradigm Corp. (NASDAQ: ARDM ). If you ...
- Business Wire•11 months ago
Aradigm Announces the EMA Has Completed Its Validation of the MAA Submission
Aradigm Corporation today announced the completed formal validation by the European Medicines Agency of the Marketing Authorisation Application for Linhaliq for the treatment of non-cystic fibrosis bronchiectasis patients with chronic lung infections with Pseudomonas aeruginosa (P.
- Business Wire•11 months ago
Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results
Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2017.
- ACCESSWIRE•11 months ago
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Aradigm Corporation And Reminds Investors With Losses To Contact The Firm
LOS ANGELES, CA / ACCESSWIRE / March 12, 2018 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aradigm Corporation ("Aradigm" ...
- ACCESSWIRE•11 months ago
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Aradigm Corporation (ARDM) & Lead Plaintiff Deadline: March 12, 2018
NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Aradigm Corporation (''Aradigm'' or the ''Company'') ...
- Zacks•11 months ago
Aradigm Files MAA for Bronchiectasis Candidate in the EU
Aradigm (ARDM) submits regulatory applications for its bronchiectasis candidate, Linhaliq, in the EU. A response from the EMA is awaited within 21 days to notify if the filing is complete.
- ACCESSWIRE•11 months ago
The Klein Law Firm Reminds Shareholders of Aradigm Corporation of a Class Action and a Lead Plaintiff Deadline of March 12, 2018 (ARDM)
NEW YORK, NY / ACCESSWIRE / March 12, 2018 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Aradigm Corporation (NASDAQ: ARDM) who purchased shares ...
- Business Wire•11 months ago
Glancy Prongay & Murray LLP Reminds Investors of the March 12, 2018 Deadline in the Class Action Lawsuit Against Aradigm Corporation
Glancy Prongay & Murray LLP reminds investors of the March 12, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Aradigm Corporation securities between July 27, 2017 and January 8, 2018, inclusive .
